Optimal MPE management requires early pulmonology referralNovember 4, 2016Lung CancerPatient & Survivor CareBreast Cancer
Pembrolizumab ‘new standard of care’ in advanced PD-L1-rich NSCLCOctober 17, 2016Lung CancerImmuno-oncology
Pembrolizumab boosts response but not survival in small study of advanced NSCLCOctober 13, 2016Lung CancerImmuno-oncology
Patients with stage 1 NSCLC more likely to die of other causes in short termOctober 11, 2016Lung Cancer
Glimmer of promise for nivolumab in neoadjuvant NSCLC therapyOctober 7, 2016Lung CancerImmuno-oncology
Clinicians call for expanded pulmonary palliative careOctober 6, 2016Lung CancerPatient & Survivor Care
